BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
MASH / NASH clinical trials and catalysts
Active industry-sponsored trials on ClinicalTrials.gov for nonalcoholic steatohepatitis: 65 (43 sponsors; 7 newly posted in the last 180 days, 2 stopped in the last 180 days; 0 new-entrant sponsors). Momentum score 22.3, rank 20 of 91 on the disease-area ranking. As of 2026-11-18.
Phase distribution: Early Phase 1 0, Phase 1 8, Phase 2 20, Phase 3 21, Phase 4 1, N/A 15.
Most active sponsors, by phase
| Sponsor | Active trials | By phase | New (window) | Upcoming readouts |
|---|---|---|---|---|
| Akero Therapeutics, Inc | 3 | P3 3 | 0 | 0 |
| Boehringer Ingelheim | 3 | P3 3 | 1 | 0 |
| Madrigal Pharmaceuticals, Inc. MDGL | 3 | P3 3 | 0 | 2 |
| GlaxoSmithKline | 4 | P3 2, P2 1, P1 1 | 0 | 0 |
| Hoffmann-La Roche | 2 | P3 2 | 0 | 0 |
| Regeneron Pharmaceuticals REGN | 7 | P3 1, P2 6 | 3 | 0 |
| Novo Nordisk A/S NVO | 2 | P3 1, P1 1 | 0 | 1 |
| Zhejiang Doer Biologics Co., Ltd. | 2 | P3 1, P2 1 | 1 | 0 |
| Eli Lilly and Company LLY | 1 | P3 1 | 0 | 0 |
| Green Cross Wellbeing | 1 | P3 1 | 0 | 0 |
| Haisco Pharmaceutical Group Co., Ltd. | 1 | P3 1 | 0 | 0 |
| Innovent Biologics (Suzhou) Co. Ltd. | 1 | P3 1 | 0 | 1 |
| Inventiva Pharma IVA | 1 | P3 1 | 0 | 0 |
| Eccogene | 3 | P1 2, P2 1 | 2 | 2 |
| Perspectum | 2 | NA 2 | 0 | 0 |
| Wuxi Hisky Medical Technology Co Ltd | 2 | NA 2 | 0 | 0 |
| 1Globe Health Institute | 1 | P1 1 | 0 | 0 |
| AB Biotics, SA | 1 | P2 1 | 0 | 1 |
| AstraZeneca AZN | 1 | P2 1 | 0 | 1 |
| Bioagile Therapeutics Pvt. Ltd. | 1 | NA 1 | 0 | 0 |
| Boryung Pharmaceutical Co., Ltd | 1 | NA 1 | 0 | 1 |
| Changchun Intellicrown Pharmaceutical Co. LTD | 1 | P1 1 | 0 | 0 |
| Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | 1 | P2 1 | 0 | 1 |
| ContextVision AB | 1 | NA 1 | 0 | 0 |
| E-Scopics | 1 | NA 1 | 0 | 0 |
Recently stopped trials
- NCT06123858 AstraZeneca - terminated: Following a reassessment of the company's pipeline priorities, the sponsor has elected to discontinue this project prior to its planned comp Non-alcoholic Steatohepatitis Registry Platform Study
- NCT04365868 Galectin Therapeutics Inc. - terminated: Based on FDA feedback, Stage 1 of NAVIGATE was analyzed as a stand-alone trial. Study was not prematurely terminated for safety reasons. Study Evaluating the Efficacy and Safety of Belapectin for the Prevention of Esophageal Varices in NASH Cirrhosis
Upcoming trial readouts (next 90 days)
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-12 est. | P3 | Madrigal Pharmaceuticals, Inc. MDGL | NCT05500222 A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis (MAESTRO-NASH-OUTCOMES) | NASH; Cirrhosis, Liver | active not recruiting | 845 |
| 2026-12 est. | P2 | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | NCT06569524 Efficacy and Safety of Recombinant Human FGF21-Fc Fusion Protein for Injection (TQA2225/AP025) in Adult Subjects With Non-alcoholic Steatohepatitis (NASH) | Non-alcoholic Steatohepatitis | recruiting | 120 |
| 2026-12-31 est. | P2 | MediciNova MNOV | NCT05464784 MN-001 in Non-alcoholic Fatty Liver Disease, Type 2 Diabetes Mellitus, and Hypertriglyceridemia | Diabetes Mellitus, Type 2; Hypertriglyceridemia; Non-Alcoholic Fatty Liver Disease | active not recruiting | 40 |
| 2026-12-31 est. | P3 | Innovent Biologics (Suzhou) Co. Ltd. | NCT06884293 A Study Comparing IBI362 vs Semaglutide in Chinese Overweight or Obese Adults With Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD) | Overweight; Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD) | active not recruiting | 479 |
| 2027-02 est. | P2 | Rivus Pharmaceuticals, Inc. | NCT07491458 A Trial to Investigate Safety, Exposure, and Efficacy of HU6 Compared With Placebo in Adult Participants With Metabolic Dysfunction-associated Steatohepatitis ( | MASH - Metabolic Dysfunction-Associated Steatohepatitis | recruiting | 180 |
| 2027-02-01 est. | P2 | AB Biotics, SA | NCT07193927 Investigation of the Efficacy of a Probiotic Mixture in Moderate Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Mechanistic Trial | MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease; Fatty Liver Disease, Nonalcoholic; | recruiting | 60 |
| 2027-02-14 est. | P2 | Hudson Biotech | NCT07481734 Tesamorelin for Reduction of Liver Fat in Adults With Fatty Liver Disease | Metabolic Associated Steatotic Liver Disease; Nonalcoholic Steatohepatitis; Hepatic Steatosis | recruiting | 120 |
Readouts in the last 180 days
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-09-29 | P3 | Inventiva Pharma IVA | NCT04849728 A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 an | NASH - Nonalcoholic Steatohepatitis | active not recruiting | 1000 |
| 2026-09-23 | P2 | Innovent Biologics (Suzhou) Co. Ltd. | NCT06937749 A Study of IBI362 in Participants With Metabolic Dysfunction-Associated Steatohepatitis (MASH) | Metabolic Dysfunction-associated Steatohepatitis (MASH) | active not recruiting | 181 |
| 2026-08-13 est. | P2 | Hinova Pharmaceuticals Inc. | NCT07308548 A Trial to Evaluate the Efficacy, Safety, PK, and PD of HP515 in Non - Alcoholic Fatty Liver Disease ( NASH/MASH ) | NAFLD (Non-alcoholic Fatty Liver Disease) | recruiting | 80 |
| 2026-08-03 | P2 | Merck Sharp & Dohme LLC MRK | NCT06465186 A Clinical Study of Efinopegdutide in People With Compensated Cirrhosis Due to Steatohepatitis (MK-6024-017) | Non-alcoholic Fatty Liver Disease; Nonalcoholic Steatohepatitis; NAFLD; Metabolic Dysfunction-associ | completed | 85 |
| 2026-07 est. | P2 | Visirna Therapeutics HK Limited | NCT06322628 A Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of VSA006 in Chinese NASH Patients | Nash | active not recruiting | 48 |
| 2026-06-26 | P2 | Hanmi Pharmaceutical Company Limited HAFC | NCT04505436 Efocipegtrutide (HM15211) in Adults With Biopsy-Confirmed Nonalcoholic Steatohepatitis (NASH) | NASH - Nonalcoholic Steatohepatitis | completed | 215 |
| 2026-06-18 | P2 | Zhejiang Doer Biologics Co., Ltd. | NCT07024212 Phase II Study Evaluating the Efficacy and Safety of DR10624 Injection in MASLD and MetALD Subjects | MASLD | active not recruiting | 110 |
| 2026-06-16 est. | P2 | Guangdong Raynovent Biotech Co., Ltd | NCT05692492 A Randomized, Double-blind, Placebo-controlled Study of ZSP1601 in Adult Subjects With Nonalcoholic Steatohepatitis (NASH) | Nonalcoholic Steatohepatitis (NASH) | active not recruiting | 180 |
| 2026-06 est. | P3 | Sagimet Biosciences Inc. SGMT | NCT06692283 A Phase 3 Study Evaluating the Safety and Efficacy of Denifanstat in Patients With MASLD and MASH | MASLD; MASH; NASH; Metabolic Dysfunction-Associated Steatotic Liver Disease; Metabolic Dysfunction-A | withdrawn |
Landscape counts: ClinicalTrials.gov, industry lead sponsors, active statuses, via the free hosted BioCatalystFeed MCP tool condition_landscape (query "nonalcoholic steatohepatitis"); readouts matched by condition text. Registry counts only; not a forecast.
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.